Preparation and Drug Release Profile of Chitosan-Siloxane Hybrid Capsules Coated with Hydroxyapatite.

Yuki Shirosaki, Yasuyo Tsukatani, Kohei Okamoto, Satoshi Hayakawa, Akiyoshi Osaka

Abstract read

In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuki ShirosakiFaculty of Engineering, Kyushu Institute of Technology, 1-1 Sensuicho, Tobata-ku, Kitakyushu 804-8550, Japan.ORCID 0000-0003-4207-4393

Yasuyo TsukataniGraduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan.

Kohei OkamotoGraduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan.

Satoshi HayakawaFaculty of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama 700-8530, Japan.

Akiyoshi OsakaGraduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan.

Funding

Japan Society for the Promotion of Science 24760549Ministry of Education, Culture, Sports, Science and Technology Kojinsenbatsu

6 · The paper itself

Abstract

Chitosan is a cationic polymer that forms polymerized membranes upon reaction with anionic polymers. Chitosan-carboxymethyl cellulose (CMC) capsules are drug delivery carrier candidates whose mechanical strength and permeability must be controlled to achieve sustained release. In this study, the capsules were prepared from chitosan-γ-glycidoxypropyltrimethoxysilane (GPTMS)-CMC. The mechanical stability of the capsules was improved by crosslinking the chitosan with GPTMS. The capsules were then coated with hydroxyapatite (HAp) by alternately soaking them in calcium chloride solution and disodium hydrogen phosphate solution to prevent rapid initial drug release. Cytochrome C (CC), as a model drug, was introduced into the capsules via two routes, impregnation and injection, and then the CC released from the capsules was examined. HAp was found to be deposited on the internal and external surfaces of the capsules. The amount of CC introduced, and the release rate were reduced by the HAp coating. The injection method was found to result in the greatest CC loading.

Indexed as

capsulechitosan–siloxane hybriddrug releasehydroxyapatite coating

Identifiers

PMID35631697

DOI10.3390/pharmaceutics14051111

PMCPMC9144734

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.